Speak directly to the analyst to clarify any post sales queries you may have.
Nuclear medicine is rapidly transforming the clinical landscape, enabling sharper diagnostics and precise therapies that drive real-world healthcare improvements. This research report delivers actionable intelligence for senior leaders seeking strategic clarity in today’s evolving nuclear medicine market.
Market Snapshot: Global Nuclear Medicine Market
The nuclear medicine market grew from USD 14.60 billion in 2024 to USD 16.05 billion in 2025 and is projected to reach USD 33.87 billion by 2032, driven by an 11.08% CAGR. This dynamic growth reflects increasing global adoption of advanced radiopharmaceuticals and nuclear imaging technologies across core medical specialties.
Scope & Segmentation
This report provides comprehensive coverage of the nuclear medicine market, dissecting critical segments, key technologies, and regional nuances influencing growth.
- Product Type: Diagnostic radiopharmaceuticals (PET isotopes, SPECT isotopes), therapeutic nuclear medicine (brachytherapy isotopes including cesium-131, iodine-125, iridium-192, palladium-103; radiopharmaceutical therapies featuring alpha and beta emitters).
- Mode of Administration: Intravenous injection, oral ingestion.
- Usage: Diagnostic procedures (PET and SPECT scanners with analog and digital platforms), therapeutic procedures.
- Application: Cardiology, endocrinology, gastroenterology, neurology, oncology, orthopedics, pulmonology.
- End Users: Academic and research institutes, diagnostic centers, hospitals (government and private).
- Key Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
- Leading Companies: 3B Pharmaceuticals GmbH, Actinium Pharmaceuticals, Inc., B J Madan & Co., Bayer AG, Bracco S.p.A., BWX Technologies, Inc., Clarity Pharmaceuticals, Curium, Eli Lilly and Company, GE HealthCare, IBA, Institute of Isotopes Co., Ltd, Isotopia Molecular Imaging Ltd., Jubilant Pharma Limited, Lantheus Holdings, Inc., Medi-Radiopharma Co., Ltd., Nordion, Northstar Medical Technologies LLC, Novartis AG, Nusano, Inc., PeptiDream Inc., Radiopharm Theranostics Limited, SHINE Technologies, LLC, Siemens Healthineers AG, Sinotau Pharmaceuticals Group, South African Nuclear Energy Corporation, State Atomic Energy Corporation Rosatom, Thor Medical AS by Nordic Nanovector ASA.
Key Takeaways: Opportunities and Strategic Insights
- Advanced imaging and targeted radiopharmaceutical therapies are accelerating the shift toward personalized medicine and more effective disease management in cardiology, oncology, and neurology.
- Strategic realignment among industry players is promoting innovation, as partnerships between academia, startups, and large imaging firms drive development of new isotopes and theranostic agents.
- Digital PET and SPECT technologies, supported by artificial intelligence, are elevating diagnostic precision, improving workflow efficiency, and enhancing patient outcomes.
- Healthcare infrastructure investments, particularly in digital imaging and data-sharing platforms, are enabling providers to scale nuclear medicine capabilities efficiently and cost-effectively.
- Growth opportunities vary significantly by region, with developed markets advancing clinical research, while emerging geographies focus on expanding accessibility to nuclear medicine services.
Tariff Impact on U.S. Nuclear Medicine Supply Chains
Recent tariff revisions in the United States are reshaping cost structures, prompting suppliers and manufacturers to reconfigure procurement strategies and invest in domestic isotope production. This environment is accelerating regulatory compliance efforts and encouraging greater operational resilience across the value chain.
Methodology & Data Sources
The research integrates qualitative insights from expert interviews with extensive secondary data analysis. Sources include peer-reviewed journals, industry reports, clinical trial databases, financial disclosures, and proprietary databases, with rigorous triangulation and validation protocols ensuring data reliability.
Why This Report Matters
- Uncover strategic opportunities in product innovation, geographic expansion, and regulatory navigation within the nuclear medicine market.
- Identify emerging growth segments and partnership models shaping the competitive landscape.
- Gain data-driven perspectives to inform capital allocation and technology adoption decisions.
Conclusion
Leaders equipped with in-depth nuclear medicine insights can navigate market shifts and capitalize on new clinical and operational opportunities. This report offers the strategic foundation necessary for informed decision-making and ongoing market leadership.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
List of Figures
Samples
LOADING...
Companies Mentioned
The key companies profiled in this Nuclear Medicine market report include:- 3B Pharmaceuticals GmbH
- Actinium Pharmaceuticals, Inc.
- B J Madan & Co.
- Bayer AG
- Bracco S.p.A.
- BWX Technologies, Inc.
- Clarity Pharmaceuticals
- Curium
- Eli Lilly and Company
- GE HealthCare
- IBA
- Institute of Isotopes Co., Ltd
- Isotopia Molecular Imaging Ltd.
- Jubilant Pharma Limited
- Lantheus Holdings, Inc.
- Medi-Radiopharma Co., Ltd.
- Nordion
- Northstar Medical Technologies LLC
- Novartis AG
- Nusano, Inc.
- PeptiDream Inc.
- Radiopharm Theranostics Limited
- SHINE Technologies, LLC
- Siemens Healthineers AG
- Sinotau Pharmaceuticals Group
- South African Nuclear Energy Corporation
- State Atomic Energy Corporation Rosatom
- Thor Medical AS by Nordic Nanovector ASA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | October 2025 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 16.05 Billion |
| Forecasted Market Value ( USD | $ 33.87 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
